INO241220C2000
- 0.05
- 0.000.00%
Inovio Pharmaceuticals Newsroom
Inovio Pharmaceuticals' INO-3107 Shows Promising Clinical Trial Results, Earns 'Buy' Rating From Analyst
Analysts Are Bullish on These Healthcare Stocks: Inovio Pharmaceuticals (INO), Replimune Group (REPL)
Oppenheimer Maintains Inovio Pharmaceuticals(INO.US) With Buy Rating, Cuts Target Price to $15
Inovio Pharma Price Target Cut to $5.00/Share From $12.00 by HC Wainwright & Co.
Oppenheimer Maintains Outperform on Inovio Pharmaceuticals, Lowers Price Target to $15
Cautious Hold Recommendation on Inovio Pharmaceuticals Amid Financial Challenges and Competitive Pressures
JMP Securities Maintains Inovio Pharmaceuticals(INO.US) With Buy Rating, Maintains Target Price $18
Inovio Pharmaceuticals: Strategic Progress and Promising Pipeline Justify Buy Rating
Inovio Pharma Is Maintained at Sector Perform by RBC Capital
Inovio Pharmaceuticals Analyst Ratings
RBC Capital Maintains Inovio Pharmaceuticals(INO.US) With Hold Rating, Cuts Target Price to $6
RBC Capital Sticks to Its Hold Rating for Inovio Pharmaceuticals (INO)
Inovio Pharma Is Maintained at Sector Perform by RBC Capital
Inovio Pharmaceuticals Analyst Ratings
RBC Cuts Price Target on Inovio Pharmaceuticals to $7 From $8, Keeps Sector Perform, Speculative Risk
Analysts Offer Insights on Healthcare Companies: Universal Health (UHS) and Inovio Pharmaceuticals (INO)
Inovio Pharmaceuticals (INO) Receives a Buy From Oppenheimer
Inovio Pharmaceuticals Analyst Ratings
Inovio Pharmaceuticals: Hold Rating Amidst Financial Concerns and INO-3107 Development Delays
RBC Cuts Price Target on Inovio Pharmaceuticals to $8 From $11, Keeps Sector Perform, Speculative Risk